Dengue vaccine study
Tuesday, 02 September, 2008
Avantogen [ASX: ACU] investee Hawaii Biotech will receive clinical trial support from the US Walter Reed Army Institute of Research (WRAIR) for its dengue fever vaccine program.
WRAIR has considerable experience with dengue fever and an established track record in emerging infectious diseases.
The recombinant-DNA-based vaccine candidate will soon undertake the clinical trial process.
Incidents of dengue, a close relative of the West Nile virus, are now growing rapidly in Australia and the Asian region.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
